BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37696934)

  • 41. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.
    Blanco JG; Sun CL; Landier W; Chen L; Esparza-Duran D; Leisenring W; Mays A; Friedman DL; Ginsberg JP; Hudson MM; Neglia JP; Oeffinger KC; Ritchey AK; Villaluna D; Relling MV; Bhatia S
    J Clin Oncol; 2012 May; 30(13):1415-21. PubMed ID: 22124095
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy.
    Chan A; Low XH; Yap KY
    J Manag Care Pharm; 2012 Jun; 18(5):385-94. PubMed ID: 22663171
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience.
    Dent SF; Botros J; Rushton M; Aseyev O; Levine MN; Parulekar WR; O'Brien P; Burnell M; Pritchard KI; Chen BE; Shepherd LE
    Breast Cancer Res Treat; 2020 Dec; 184(3):733-741. PubMed ID: 32940847
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes.
    Liutkauskiene S; Grizas S; Jureniene K; Suipyte J; Statnickaite A; Juozaityte E
    BMC Cancer; 2018 Apr; 18(1):453. PubMed ID: 29678165
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cardiac safety of liposomal anthracyclines.
    Ewer MS; Martin FJ; Henderson C; Shapiro CL; Benjamin RS; Gabizon AA
    Semin Oncol; 2004 Dec; 31(6 Suppl 13):161-81. PubMed ID: 15717742
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical and histological features of second breast cancers following radiotherapy for childhood and young adult malignancy.
    Demoor-Goldschmidt C; Supiot S; Mahé MA; Oberlin O; Allodji R; Haddy N; Helfre S; Vigneron C; Brillaud-Meflah V; Bernier V; Laprie A; Ducassou A; Claude L; Diallo I; de Vathaire F
    Br J Radiol; 2018 Jun; 91(1086):20170824. PubMed ID: 29493262
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials.
    Smith LA; Cornelius VR; Plummer CJ; Levitt G; Verrill M; Canney P; Jones A
    BMC Cancer; 2010 Jun; 10():337. PubMed ID: 20587042
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low-dose anthracyclines in childhood Acute Lymphoblastic Leukemia (ALL): no cardiac deterioration more than 20 years post-treatment.
    Brouwer CA; Gietema JA; van den Berg MP; Bink-Boelkens MT; Elzenga NJ; Haaksma J; Kamps WA; Vonk JM; Postma A
    J Cancer Surviv; 2007 Dec; 1(4):255-60. PubMed ID: 18648960
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy.
    Teepen JC; van Leeuwen FE; Tissing WJ; van Dulmen-den Broeder E; van den Heuvel-Eibrink MM; van der Pal HJ; Loonen JJ; Bresters D; Versluys B; Neggers SJCMM; Jaspers MWM; Hauptmann M; van der Heiden-van der Loo M; Visser O; Kremer LCM; Ronckers CM;
    J Clin Oncol; 2017 Jul; 35(20):2288-2298. PubMed ID: 28530852
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Electrocardiographic and biochemical analysis of anthracycline induced cardiotoxicity in breast cancer patients from Southern Sri Lanka.
    Sandamali JAN; Hewawasam RP; Fernando MACSS; Jayatilaka KAPW
    BMC Cancer; 2023 Mar; 23(1):210. PubMed ID: 36870959
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiovascular disease in survivors of childhood cancer.
    Bansal N; Amdani SM; Hutchins KK; Lipshultz SE
    Curr Opin Pediatr; 2018 Oct; 30(5):628-638. PubMed ID: 30124579
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors.
    Armenian SH; Gelehrter SK; Vase T; Venkatramani R; Landier W; Wilson KD; Herrera C; Reichman L; Menteer JD; Mascarenhas L; Freyer DR; Venkataraman K; Bhatia S
    Clin Cancer Res; 2014 Dec; 20(24):6314-23. PubMed ID: 24947931
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation.
    Zambetti M; Moliterni A; Materazzo C; Stefanelli M; Cipriani S; Valagussa P; Bonadonna G; Gianni L
    J Clin Oncol; 2001 Jan; 19(1):37-43. PubMed ID: 11134193
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk of second breast cancer in female Hodgkin's lymphoma survivors: a meta-analysis.
    Ibrahim EM; Abouelkhair KM; Kazkaz GA; Elmasri OA; Al-Foheidi M
    BMC Cancer; 2012 May; 12():197. PubMed ID: 22639888
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
    Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
    Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
    Mackey JR; Martin M; Pienkowski T; Rolski J; Guastalla JP; Sami A; Glaspy J; Juhos E; Wardley A; Fornander T; Hainsworth J; Coleman R; Modiano MR; Vinholes J; Pinter T; Rodríguez-Lescure A; Colwell B; Whitlock P; Provencher L; Laing K; Walde D; Price C; Hugh JC; Childs BH; Bassi K; Lindsay MA; Wilson V; Rupin M; Houé V; Vogel C;
    Lancet Oncol; 2013 Jan; 14(1):72-80. PubMed ID: 23246022
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Breast Cancer Risk in Childhood Cancer Survivors Without a History of Chest Radiotherapy: A Report From the Childhood Cancer Survivor Study.
    Henderson TO; Moskowitz CS; Chou JF; Bradbury AR; Neglia JP; Dang CT; Onel K; Novetsky Friedman D; Bhatia S; Strong LC; Stovall M; Kenney LB; Barnea D; Lorenzi E; Hammond S; Leisenring WM; Robison LL; Armstrong GT; Diller LR; Oeffinger KC
    J Clin Oncol; 2016 Mar; 34(9):910-8. PubMed ID: 26700127
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience.
    Diamandidou E; Buzdar AU; Smith TL; Frye D; Witjaksono M; Hortobagyi GN
    J Clin Oncol; 1996 Oct; 14(10):2722-30. PubMed ID: 8874333
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapy-related myeloid neoplasm in early breast cancer patients treated with adjuvant chemotherapy.
    Lee JW; Oh H; You JY; Lee ES; Lee JH; Song SE; Lee NK; Jung SP; An JS; Cho KR; Kim CY; Park KH
    Eur J Cancer; 2023 Sep; 191():112952. PubMed ID: 37473463
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Echocardiographic Detection of Cardiac Dysfunction in Childhood Cancer Survivors: How Long Is Screening Required?
    Ramjaun A; AlDuhaiby E; Ahmed S; Wang L; Yu E; Nathan PC; Hodgson DC
    Pediatr Blood Cancer; 2015 Dec; 62(12):2197-203. PubMed ID: 26146944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.